输血治疗结合mFOLFOX6化疗对结直肠癌患者的应用效果  

Effect of Blood Transfusion Combined with mFOLFOX6 Chemotherapy on Patients with Colorectal Cancer

作　　者：代儒俊 DAI Rujun(The Affiliated Cancer Hospital of Guizhou Medical University,Guiyang 550000,China)

机构地区：[1]贵州医科大学附属肿瘤医院,贵州贵阳550000

出　　处：《中外医学研究》2024年第36期118-121,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探究输血治疗结合mFOLFOX6化疗对结直肠癌患者的应用效果。方法:选取2022年7月—2023年7月贵州医科大学附属肿瘤医院收治的100例结直肠癌患者作为研究对象,按抽签法分为对照组和观察组,每组各50例。对照组使用mFOLFOX6化疗,观察组予以输血治疗结合mFOLFOX6化疗。比较两组肿瘤标志物水平[甲胎蛋白(AFP)、糖类抗原19-9(CA19-9)、细胞质胸苷激酶(TK1)、癌胚抗原(CEA)]、机体免疫能力[成熟的T淋巴细胞(CD3^(+))、辅助性T细胞(CD4^(+))、细胞毒性T细胞(CD8^(+))]、临床疗效、生存质量及不良反应发生率。结果:治疗后,两组肿瘤标志物水平下降,差异无统计学意义(P>0.05)。治疗后,两组免疫功能指标下降,观察组指标高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组生存质量评分高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组临床总有效率高于对照组,差异有统计学意义(P<0.05)。结论:mFOLFOX6化疗结合输血治疗用于结直肠癌患者有助于降低其肿瘤标志物水平,且患者的免疫系统没有受到明显影响,安全性较高。Objective:To explore the effects of blood transfusion therapy combined with mFOLFOX6 chemotherapy on the level of tumor markers and immune capacity in patients with colorectal cancer.Method:A total of 100 patients with colorectal cancer admitted to the Affiliated Cancer Hospital of Guizhou Medical University from July 2022 to July 2023 were selected as the study objects and divided into control group and observation group according to lottery method,with 50 cases in each group.The control group received mFOLFOX6 chemotherapy,while the observation group received blood transfusion therapy combined with mFOLFOX6 chemotherapy.The levels of tumor markers[alpha-fetoprtein (AFP),carbohydrate antigen 19-9 (CA19-9),Thymidinekinase (TK1),Carcinoembryonic antigen (CEA)],immune capacity[mature T lymphocytes (CD3^(+)),helper T cells (CD4^(+)),cytotoxic T cells (CD8^(+))],clinical efficacy,quality of life and incidence of adverse reactions were compared.Result:After treatment,the levels of tumor markers in both groups decreased,and difference was not statistically significant (P>0.05).After treatment,the immune function indexes of all groups decreased,and the observation group was higher than the control group,and the difference was statistically significant (P<0.05).After treatment,the scores of quality of life in the observation group were higher than those in the control group,and the difference was statistically significant (P<0.05).After treatment,the incidence of adverse reactions in the observation group was lower than that in control group,and the difference was statistically significant (P<0.05).After treatment,the total clinical effective rate in obsrvation group was higher than that in control group,and the difference was statistically significant (P<0.05).Conclusion:mFOLFOX6 chemotherapy combined with blood transfusion can help reduce the level of tumor markers in patients with colorectal cancer,and the immune system of patients is not significantly affected,and the safety is high.

关 键 词：输血治疗 mFOLFOX6化疗 结直肠癌 肿瘤标志物 机体免疫能力 

分 类 号：R73[医药卫生—肿瘤]